Gathering Records to Evaluate Antiretroviral Treatment-Malawi ( GREAT )

Overview

To achieve global goals for the treatment of HIV, most high-prevalence countries are experimenting with and scaling up differentiated service delivery models (DSD). A handful of efforts have been formally described and evaluated in the literature; many others are being implemented formally or informally under routine care, without a research or evaluation goal. For most countries, however, we have little evidence on the big picture-the proportion of clinics offering alternative models, eligibility criteria and the proportion of patients considered eligible, the number of patients actually participating, health outcomes such as viral suppression, empirical resource utilization compared to traditional care, variations among the models, duration of patient participation, fidelity to model guidelines, effects on clinic efficiency, and sustainability without external donor support. AMBIT is a set of data synthesis, data collection, and data analysis activities aimed at generating information for near- and long-term decision making and creating an approach and platform for ongoing evaluation of differentiated models of HIV treatment delivery in the future. The project will collect and analyze a wide range of existing data sets pertinent to DSD. This protocol is for an analysis of existing medical record data collected by the Ministry of Health, implementing partners, and other completed, ongoing, or new evaluations, trials, and observational studies. Outcomes to be reported include coverage/uptake of DSD, patients' outcomes, and distribution of each model. There will be no study interaction with individual patients, providers, caregivers, or others for this analysis.

Full Title of Study: “Analysis of Existing Medical Record Data to Evaluate Coverage, Uptake, Benefits, and Costs of Differentiated Models of Service Delivery for HIV Treatment in Africa (Malawi)”

Study Type

  • Study Type: Observational
  • Study Design
    • Time Perspective: Prospective
  • Study Primary Completion Date: October 2024

Interventions

  • Other: Routine medical record data collection
    • The study will collect routine medical record data from the electronic medical record system, other electronic databases, and paper charts.

Arms, Groups and Cohorts

  • Patients enrolled in differentiated service delivery models
  • Patients not enrolled in DSD models

Clinical Trial Outcome Measures

Primary Measures

  • Patient-months enrolled in any DSD model
    • Time Frame: 12 months
    • % of all patient-months of ART provided for the cohort that are provided within DSD models
  • Patient-months enrolled in any DSD model
    • Time Frame: 24 months
    • % of all patient-months of ART provided for the cohort that are provided within DSD models
  • Patient-months enrolled in any DSD model
    • Time Frame: 6 months
    • % of all patient-months of ART provided for the cohort that are provided within DSD models

Participating in This Clinical Trial

Inclusion Criteria

  • ≥ 15 years old – Patients accessing care for HIV within the data collection period – In any HIV transmission risk group Exclusion Criteria:

  • None

Gender Eligibility: All

Minimum Age: 15 Years

Maximum Age: N/A

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Boston University
  • Collaborator
    • Bill and Melinda Gates Foundation
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Official(s)
    • Sydney B Rosen, Study Director, Boston University School of Pubic Health
  • Overall Contact(s)
    • Sydney B Rosen, 6173582251, sbrosen@bu.edu

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.